国际抗高血压新药研发进展  

Progress in the international development of new anti-hypertensive medicines

作　　者：杜海洲[1] 张建平[1] 吕婷[1] 刘桂玲[1] 王天津[1] 刘娜[1] 刘伟[1] 

机构地区：[1]解放军医学图书馆,北京100039

出　　处：《中国新药杂志》2010年第24期2290-2297,2302,共9页Chinese Journal of New Drugs

摘　　要：根据美国药物研究与生产商协会(PhRMA)的报告和《新药数据库》等对目前国际上32种治疗高血压新药的临床开发研究情况进行统计分析。参照《中国高血压防治指南》(2005年)进行分类,在目前正在开发的治疗高血压的药物中,仅有常规抗高血压药2类各1种,新型制剂为10类16种,已获得批准或未获得批准的药物加入新技术药物有4类6种,将已获得批准用于治疗其他疾病的药物用于治疗高血压的临床试验2类各1种。结果显示,新型制剂明显多于常规药物,并且治疗性疫苗和双重抑制剂都可能成为治疗高血压的新药,但抗高血压新药研发喜忧参半。This paper is based on the report of 2009： New Medicines in Development for Heart Disease and Stroke and the Medicines in Development Database published by the Pharmaceutical Research and Manufacturers of America（PhRMA）.Thirty-two new medicines for hypertension currently in the clinical development are statistically analyzed.According to the classification in the Chinese Guidelines for Prevention,Detection,Evaluation,and Treatment of High Blood Pressure,there are only each one agents in 2 classes of the traditional 5 classes,and 16 agents in 10 newer classes;6 agents in 4 classes are ones approved or not added with new technologies;and each one agent in 2 classes are approved for other diseases.The results show that newer agents are much more than older ones,and both therapeutic vaccines and dual acting receptor antagonists will be the newer anti-hypertensive agents,but the new medicines in the development for hypertension are mingled with hope and fear.

关 键 词：抗高血压药 临床试验 新药研发 

分 类 号：R979.1[医药卫生—药品]